ArticleBMJ open diabetes research & care2024

Cardiovascular and mortality benefits of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide 1 receptor agonists as third-step glucose-lowering medicine in patients with type 2 diabetes: a retrospective cohort analysis.

Thomas A McCormick et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.